When considering the purchase of KPV for scientific or therapeutic purposes, it is important to understand both its role within a broader gastrointestinal inflammation research framework and the specific details that define its quality and usability.
Gastrointestinal Inflammation Research Formula
The peptide cocktail often used in preclinical studies of gut repair includes three key components. First, BPC-157 is a well documented body protective compound derived from human gastric juice; it promotes angiogenesis, collagen synthesis and epithelial cell migration. Second, KPV is a tripeptide fragment that selectively binds to the Mas receptor and has been shown to reduce pro-inflammatory cytokine production while enhancing mucosal barrier integrity. Third, N-Acetyl Larazotide is an acetylated derivative of larazotide acetate, a tight junction regulator that can restore intestinal permeability in models of inflammatory bowel disease.
Together these molecules create a synergistic effect: BPC-157 accelerates tissue healing, KPV dampens inflammation and supports mucosal resilience, and N-Acetyl Larazotide stabilises cell–cell adhesion. Researchers routinely combine them at concentrations ranging from 1 µM to 10 µM in vitro or use equivalent doses in vivo depending on the animal model.
Product Description
The product sold as KPV is typically provided in a sterile, lyophilized powder that is easy to reconstitute with high-purity water for injection. The manufacturer offers the peptide in vial sizes of 500 mg and 1 g, which correspond to approximately 2 mmol and 4 mmol of active ingredient respectively. Each vial is sealed under nitrogen to prevent oxidation and stored at −20 °C until use.
The packaging includes a detailed certificate of analysis that confirms purity by high-performance liquid chromatography (HPLC) and mass spectrometry. The label states that the peptide is free from contaminants such as endotoxins, heavy metals or residual solvents. For researchers working in regulated environments, the product also meets cGMP standards and has been tested for sterility.
Peptide Specifications
Molecular Formula: C17 H25 N5 O4 Molecular Weight: 411.35 Da Isomeric Composition: The KPV peptide is synthesized as a single enantiomer (L-configuration) to ensure biological activity. Purity: ≥98 % by weight, verified through analytical HPLC. Stability: The lyophilized powder remains stable for up to 24 months when stored at −20 °C; it should be protected from light and moisture during handling. Upon reconstitution with sterile water the solution can be kept at 4 °C for a maximum of 48 hours before use.
Reconstitution Instructions
To prepare a working solution, add the required volume of sterile, nuclease-free water to achieve the desired molarity. For example, adding 100 µL of water to a 500 mg vial yields a concentration of approximately 5 mM. Vortex gently and allow the powder to dissolve completely before use. Avoid repeated freeze–thaw cycles; aliquot into smaller volumes if long-term storage is necessary.
Applications
In cell culture, KPV is typically added to media at concentrations ranging from 0.1 µM to 10 µM depending on the experimental endpoint. In animal models of colitis or ulcerative jejunitis, doses between 5 mg/kg and 20 mg/kg administered via intraperitoneal injection have shown significant reductions in histological inflammation scores.
Key Advantages
High purity and cGMP compliance reduce variability across experiments.
The tripeptide format allows for straightforward synthesis and cost-effective scaling.
When used alongside BPC-157 and N-Acetyl Larazotide, it provides a comprehensive approach to restoring barrier function while mitigating inflammatory signaling pathways.
In summary, purchasing KPV from a reputable supplier involves evaluating the purity certificates, understanding the storage conditions, and integrating the peptide into a well-designed experimental protocol that includes complementary agents such as BPC-157 and N-Acetyl Larazotide for maximal therapeutic impact in gastrointestinal inflammation research.
